This does not bode well for Eli Lilly’s new medicine Mounjaro as the head- to- head study conducted and published on Monday revealed
that cases on Mounjaro lost way lesser weights than those on Novo Nordisk’s Ozempic.
Investigating the news electronic health record of over 18 000 US cases between May 2022—September 2023, several authors identified the problems
in patients who began taking the two fitted drugs and published the results in JAMA Internal Medicine.
Patients’ average age was 52 years, and the majority were female patients; the average weight of the patients was 110 kilograms (242 pounds).
Type 2 diabetes was identified in 52 percent of the patients.
ref test subjects in the utmost cases were found to have five percent or lesser weight loss after a time,
those belonging to the Mounjaro category manifested higher probability to have weighed lesser while on the diet
See More